Form 4: Oncology Institute Director Johnson Acquires Shares and Warrants in Private Placement
SEC Form 4
Karen Marie Johnson, a director at Oncology Institute, purchased shares and warrants through a private placement, increasing her holdings in the company.
Summary
- Karen Marie Johnson, a director of Oncology Institute, Inc., acquired 36,224 shares of common stock and 18,112 common warrants on March 26, 2025.
- The transactions were part of a private placement where Johnson purchased units consisting of two shares of common stock and one common warrant.
- Each unit was priced at $2.2084, with the common stock valued at $1.0417 per share and the common warrant at $0.1250.
- Following the transaction, Johnson directly owns 203,409 shares of common stock and 18,112 common warrants.
- The common warrants have an exercise price of $1.198 and expire on March 26, 2030.
- Johnson is restricted from exercising the warrants if it would result in her beneficially owning more than 4.99% of the company's outstanding common stock.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as a director is increasing their stake in the company, which is generally a good sign. However, it's a private placement, which can sometimes be dilutive.
Positives
- Director's increased investment signals confidence in the company's future prospects.
- The private placement provides the company with additional capital.
Risks
- The warrant exercise restriction could limit potential gains for the director.
- The private placement could dilute existing shareholders' equity.
Industry Context
Directors purchasing shares in their own companies is generally viewed positively, as it aligns their interests with those of other shareholders. Private placements are a common method for companies to raise capital, particularly for growth-stage companies like Oncology Institute.
Stakeholder Impact
- Shareholders may experience dilution due to the issuance of new shares in the private placement.
- The company benefits from the capital raised through the private placement.
Key Dates
| Date | Description |
|---|---|
| 03/24/2025 | Date of the Securities Purchase Agreement for the Private Placement. |
| 03/26/2025 | Date of the transaction where Johnson acquired shares and warrants. |
| 03/26/2030 | Expiration date of the common warrants. |
| 03/28/2025 | Date of signature for the SEC Form 4 filing. |
Keywords
Oncology Institute, Karen Marie Johnson, private placement, common stock, common warrant, director, acquisition, beneficial ownership, TOI
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.